A Elif Anil

Learn More
Previous studies have suggested decreased N-methyl-D-aspartate (NMDA)-type glutamate receptor function may contribute to increased negative symptoms in patients with schizophrenia. Consistent with this hypothesis, glycine, a co-agonist at NMDA receptors, has been reported to improve negative symptoms associated with the illness. This study was performed to(More)
The following study was conducted to adapt the Auditory Consonant Trigram Test (ACT) to Turkish, acquire a new and larger set of normative data, and finally investigate the reliability and validity of the adapted version. The data were collected from a sample of 236 healthy individuals. To test the validity of the Turkish version of ACT, the normative(More)
The aim of this study was to reexamine and compare the characteristics of the deficit and nondeficit schizophrenic patients. This cross-sectional study consisted of 62 in- and out-patients, 18-65 years of age, diagnosed with schizophrenia according to DSM-IV. The sociodemographic variables, premorbid adjustment, clinical course and general functioning level(More)
(SSRI), tipik nöroleptikler ve yeni kuflak antipsikotikler, duygudurum düzenleyicileri, elektrokonvülzif tedavi (EKT) ve N-metil-D-aspartat (NMDA) agonistleri bafll›klar› alt›nda incelenmek-tedir. SUMMARY: A Review on Augmentation of Clozapine Treatment Clozapine is one of the most effective pharmacological agents in the treatment of treatment-resistant(More)
Clozapine is one of the most effective pharmacological agents in the treatment of treatment-resistant patients with schizophrenia, schizoaffective and bipolar disorder. Nevertheless, there is still an important proportion of patients who do not respond to clozapine treatment given at a sufficient dose and duration. Some patients cannot tolerate the dosage(More)
  • 1